Compare Novo Nordisk A/S (NVO) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs BlackRock TCP Capital Corp — how do they compare? Novo Nordisk A/S trades at $45.1 (market cap $198.57B), while BlackRock TCP Capital Corp trades at $4.03 (market cap $338.13M). The key difference: Novo Nordisk A/S is far larger — about 587.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.86%). Which is the better fit depends on your goals.
| NVO | TCPC | |
|---|---|---|
Market Cap | $198.57B | $338.13M |
Sector | Health | Financials |
52-Week High | $63.98 | $7.22 |
52-Week Low | $35.29 | $3.13 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | 18.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
TCPC trades at $4.07, showing no daily change. The stock exhibits bearish technical signals with flat support/resistance at $4. Recent earnings showed mixed results with Q2 2026 beating estimates at $0.22 EPS versus $0.20 expected. The company faces fundamental challenges with negative revenue of -$77.27M and net income of -$88.93M for 2025, though it maintains a dividend payout of $0.17 quarterly.
Investment outlook remains cautious due to negative profitability metrics and ongoing strategic review. The company's portfolio sale and leverage reduction provide some stability, but persistent revenue declines and class action lawsuits present significant risks. Analyst consensus leans neutral with 61.5% hold ratings, reflecting uncertainty about the company's turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
